ArticleInvestigational new drugs2020

A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.

Meijuan Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.